Publications by authors named "Haifa Al-Ali"

Claim this Profile
A
Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations.
Marcus Bauer, Christoforos Vaxevanis, Nadja Jaekel, Hubert Hackl, Andreas Wilfer, Haifa Kathrin Al-Ali

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology.
Susann Schulze, Sabrina Jotschke, Robby Engelmann, Beatrice Ludwig-Kraus, Frank Bernhard Kraus, Haifa Kathrin Al-Ali

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.
Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson

Acta Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis.
Pankit Vachhani, Paola Guglielmelli, Jennifer Repp, J E Hamer-Maansson, Evan Braunstein, Haifa Kathrin Al-Ali

Leuk Lymphoma· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Real-World Experience With Ruxolitinib for Myelofibrosis.
Haifa Kathrin Al-Ali, Aaron T Gerds, Michael R Grunwald, Jingbo Yu

Clin Lymphoma Myeloma Leuk· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient.
Bruno Griesler, Susann Schulze, Thomas Kegel, Christine Dierks, Pablo Villavicencio-Lorini, Haifa Kathrin Al-Ali

Front Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN).
Kirsi Manz, Florian H Heidel, Steffen Koschmieder, Rudolf Schlag, Jörg Lipke, Haifa Al-Ali

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.
Dietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, Bart J Biemond, Haifa Al-Ali

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
Nikolaus Christian Simon Mezger, Tobias Paul Seraphin, Robert Ballé, Mirko Griesel, Yvonne Walburga Joko-Fru, Haifa Kathrin Al-Ali

J Natl Cancer Inst· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.
Martin Griesshammer, Haifa Kathrin Al-Ali, Jan-Niklas Eckardt, Michael Fiegl, Joachim Göthert

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data.
Karina C Manz, Anja Mocek, Bashar Morouj, Katharina Merker, Marc Feuerbach, Haifa Kathrin Al-Ali

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib.
Haifa Kathrin Al-Ali, Andrew T Kuykendall, Catherine E Ellis, Janardhan Sampath, Ruben Mesa

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
Stefanie Jilg, Juliana Schwaab, Katja Sockel, Carl C Crodel, Valeska Brueckl, Haifa K Al-Ali

Ann Hematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy

Lancet Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al-Ali, Heiko Becker, Thorsten Götze

Ann Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of immune evasion in myeloid sarcomas with disease manifestation and patients' survival.
Marcus Bauer, Astrid Monecke, Hubert Hackl, Andreas Wilfer, Nadja Jaekel, Haifa Kathrin Al-Ali

Front Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato

Ann Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Marcus Bauer, Nadja Jäkel, Andreas Wilfer, Anja Haak, Markus Eszlinger, Haifa Kathrin Al-Ali

Oncoimmunology· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Susanne Isfort, Kirsi Manz, Lino L Teichmann, Martina Crysandt, Andreas Burchert, Haifa Kathrin Al-Ali

Ann Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Aaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie

Lancet Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).
Sabine Felser, Julia Rogahn, Lina Hollenbach, Julia Gruen, Philipp le Coutre, Haifa Kathrin Al-Ali

Cancer Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.
Robby Engelmann, Nadja Jaekel, Sabrina Jotschke, Beatrice Ludwig-Kraus, Frank Bernhard Kraus, Haifa Kathrin Al-Ali

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study.
Francesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, Mike W Zuurman, Rajendra Sarkar

Cancers (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali

Ann Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Srdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie

Lancet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis